Matching action to need

The Index has identified four key findings. Three findings link to whether companies match access to need. In R&D there is evidence that the industry responds to externally identified needs. However, good practice in aligning product affordability and availability with need is limited. Six companies systematically match activities to local priorities when strengthening health systems. Alongside this, the Index also finds that while companies are increasingly organised in their efforts to increase access to medicine: these efforts can be placed at risk without the compliance systems to support them.

Collaborative Research Models Appear Effective In Engaging The Industry In Developing Urgently Needed Products With Low Commercial Potential

Collaborative research models appear effective in engaging the industry in developing urgently needed products with low commercial potential

The top 20 pharmaceutical companies are developing 420 products for the 51 most burdensome diseases and conditions in low- and middle-income countries. This includes more than 100 products that have entered the pipeline since the previous Index and 151 with low commercial potential but which are urgently needed, mainly by the poor.
Continue reading
Good Practice In Making Products Affordable And Available Is Limited

Good practice in making products affordable and available is limited

The Index analyses how pharmaceutical companies deploy medicines, diagnostics and vaccines once they have emerged from the pipeline. It finds that companies generally do not systematically target populations with the highest needs in their registration, pricing and licensing actions.
Continue reading
Companies Increasingly View Access To  Medicine As A Way To Develop Their Business In Emerging Markets

Companies increasingly view access to medicine as a way to develop their business in emerging markets

Companies are refining the ways they organise efforts to increase access to medicine. Most (17) now have a detailed access-to-medicine strategy. AbbVie, Astellas and Daiichi Sankyo are the exceptions. While they have approaches for increasing access to medicine, they have not set out an overarching access strategy.
Continue reading
Six Companies Systematically Match Activities To Local Priorities When Strengthening Health Systems.

Six companies systematically match activities to local priorities when strengthening health systems.

Gaps in local healthcare infrastructure are hampering the delivery of medicines and vaccines to millions of people, mainly in poorer countries. Most pharmaceutical companies in the Index are building a range of health system capacities in low- and middle-income countries. The 2016 Index has identified six pharmaceutical companies that are consistently addressing independently prioritized gaps through their capacity building programmes: AstraZeneca, GSK, Johnson & Johnson, Merck & Co., Inc., Merck KGaA and Novartis.
Continue reading

Sign up to receive updates about our work.